Skip to main content

You are here

Past Investments

Terumo

Amnion, Inc.

Acquired by Gambro BCT; Name changed to CaridianBCT July 14, 2008; CaridianBCT aquired by Terumo March 2011.
Tokyo Stock Exchange: 4543


Agenus

Antigenics, Inc.

Antigenics acquired Aronex Pharmaceuticals in 2001; Name change to Agenus Jan 2011.
NASDAQ: AGEN


Biomerieux

Bacterial Barcodes

Acquired by bioMérieux, Inc. in 2006.
NYSE Euronext: BIM


Forum Pharmaceuticals

Forum Pharmaceuticals

Formerly EnVivo Pharmaceuticals.


Genosys Biotechnologies, Inc.

Acquired by Sigma-Aldrich in 1998.
NASDAQ: SIAL


Lark

Lark Technologies, Inc.

Acquired by Genaissance Pharmaceuticals in 2004; Genaissance Pharmaceuticals acquired by Clinical Data Inc. in October 2005; Clinical Data Inc. Acquired by Forest Laboratories in 2011.
NYSE Euronext: FRX


Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc.

NASDAQ: LXRX


Medical Metrics

Medical Metrics


Meretek Diagnostics, Inc.

Subsidiary of Otsuka America.


MithraGen

Formally MithraTech.


Oncovance Technologies


GE Healthcare

PrimaCIS Health information Technology, Inc.

PrimaCIS was acquired by MedicaLogic in 1999; acquired by GE Medical Systems April 1, 2002.
NYSE Euronext: GE


Repros

Repros Therapeutics Inc.

Formerly Zonagen, Inc.
NASDAQ: RPRX


Sapphire Therapeutics

Sapphire Therapeutics

Sapphire is a biopharmaceutical company committed to developing and commercializing promising compounds that are ready for clinical or pre-clinical testing in oncologic and metabolic disease. The most advanced drug candidate in Sapphire's pipeline is a small molecule ghrelin agonist. Switzerland-based pharmaceutical group Helsinn has acquired the US-based biopharmaceutical company, Sapphire Therapeutics. Phase II human clinical trials for cancer cachexia.


Skillsoft

Smartforce

Acquired by SkillSoft in 2002.


Perkin-Elmer

Spectral Genomics

Acquired by PerkinElmer, Inc. in 2006.
NYSE Euronext: PKI


Valentis

Valentis, Inc.

Formerly GeneMedicine, Inc.; merged with Megabios in 1999 and became Valentis.


Inovio

VGX Pharmaceuticals

Formerly ADViSYS; acquired by Inovio Biomedical Corporation in 2009.
NYSE Euronext: INO